Business Context and Reporting Period
Company: Alzamend Neuro, Inc. (ALZN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended July 31, 2025
Business Overview: Alzamend is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The company has two primary product candidates: AL001 (a lithium-based ionic cocrystal) and ALZN002 (a cell-based therapeutic vaccine). The company has not generated any product revenue to date and relies on equity and debt financing.
Key Financial Metrics
| Metric | Q1 2025 (Ended July 31) | Q1 2024 (Ended July 31) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,702,684) | $(974,411) |
| Loss Per Share (Basic & Diluted) | $(1.28) | $(11.42) |
| Cash and Cash Equivalents | $5,620,872 | $1,193,950 |
| Working Capital | $4,945,519 | Not explicitly stated (Negative Equity) |
| Total Assets | $6,326,751 | Not provided in summary table |
| Total Liabilities | $983,311 | Not provided in summary table |
| Stockholders' Equity | $5,343,440 | $(1,212,319) |
| Accumulated Deficit | $(61,237,945) | $(54,994,819) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 181% to $2.7 million from $962,405 in the prior year period.
- Research & Development (R&D): Increased 743% to $1.74 million, driven primarily by $1.66 million in clinical trial fees for the Phase IIA brain imaging study with Massachusetts General Hospital. In the prior year, clinical trial fees were nil.
- General & Administrative (G&A): Increased 27% to $959,334, largely due to higher legal fees ($183,000 vs. $85,000) related to the termination of the ALZN002 clinical trial CRO contract, and increased marketing fees.
- Capital Structure: The company executed a 1-for-9 reverse stock split effective May 12, 2025. Common shares outstanding increased from 778,733 to 3,139,861 during the quarter due to the conversion of Series B and Series C preferred stock.
- Financing Activity: Net cash provided by financing activities was $4.035 million, primarily from the issuance of Series C Convertible Preferred Stock. This contrasts with $1.96 million in the prior year period.
- Liquidity: Cash balances increased by $1.67 million to $5.62 million, compared to a $0.82 million increase in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. The company expects to incur net losses in the foreseeable future and requires additional capital to fund operations and clinical trials.
- Clinical Progress:
- AL001: The company initiated a "Lithium in Brain" Phase II clinical trial in May 2025 with Massachusetts General Hospital. Nonclinical data showed AL001 achieves higher brain lithium concentrations with lower plasma levels compared to lithium carbonate.
- ALZN002: The company terminated its contract with CRO Biorasi, LLC, in February 2024 and is seeking a replacement to continue the Phase I/IIA trial.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to insufficient accounting resources, restricting the ability to perform sufficient reviews of manual journal entries and account reconciliations. Remediation is ongoing.
- Future Funding: The company plans to seek additional funding through public equity, private equity, and debt financings. Failure to obtain funding could force the delay or elimination of R&D programs.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $5.6 million cash balance against the current burn rate of approximately $2.4 million per quarter to assess the timeline for the next capital raise.
- ALZN002 CRO Status: Confirm the engagement status of a new Contract Research Organization (CRO) to replace Biorasi, LLC, as this is critical for the continuation of the ALZN002 clinical trial.
- Preferred Stock Conversions: Review the terms of the Series C Convertible Preferred Stock (15% dividend accrual) and the potential dilution impact of the conversion price mechanisms (floor price of $0.90).
- Internal Control Remediation: Monitor the progress of hiring additional accounting staff to remediate the material weakness in financial reporting controls.
- Licensing Milestones: Track upcoming royalty and milestone payment obligations to the University of South Florida Research Foundation, particularly the $1.25 million payment due upon the first patient treated in a Phase III clinical trial for AL001.